CompletedPhase 1NCT01113281

Dose-Escalation Study on Safety and Immunogenicity of VPM1002 in Comparison to BCG in Healthy Volunteers in South Africa

Studying Tuberculosis

Last synced from ClinicalTrials.gov

ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing data

Key facts

Sponsor
Serum Life Science Europe GmbH
Principal Investigator
Mada Ferreira, MD
Farmovs-Parexel, Bloemfontein, RSA
Intervention
VPM1002 live vaccine(biological)
Enrollment
24 enrolled
Eligibility
18-45 years · All sexes
Timeline
2010 – 2011

Study locations (1)

Collaborators

Farmovs-Parexel Bloemfontein, Republic of South Africa (Clinical Site) · Triclinium Johannesburg, RSA (Monitoring and Overall Management of the study) · University of Stellenbosch · HJ-CTC George, RSA (Statistics & Report)

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Open NCT01113281 on ClinicalTrials.gov

Other trials for Tuberculosis

Additional recruiting or active studies for the same condition.

See all trials for Tuberculosis →

← Back to all trials